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Editorial
When today scientists and bioprocess engineers look at a
Microbial Cell Factory for the production of a protein or
a metabolite of commercial or research interest, they think
at the microorganism of choice first from a (i) molecular,
then from a (ii) metabolic and finally from a (iii) process
point of view. Analyses and manipulations of the path-
way(s) involved in the synthesis of the desired product
and how this pathway(s) interacts with the overall cell
functions and activities are indeed steps required to
obtain high yield of the product (g of compound per g of
substrate), high production (g/l) and high productivity
(g/l/h). Conceptually, the whole set of biochemical reac-
tions that take place in the microbial cell factory should be
considered. This is valid for processes involving natural
and/or recombinant products in wild type and/or engi-
neered hosts.
Definitely, the whole approach was not straightforward
when it was anticipated about 20 years ago by James Bai-
ley, who proposed the development of a new discipline
called Metabolic Engineering defined as "the improve-
ment of cellular activities by manipulations of enzymatic,
transport, and regulatory functions of the cell with the use
of recombinant DNA technology" [1]. The development
in genomic, molecular and bioinformatic tools together
with high-throughput systems enormously speeded up
the development of the existing as well as of new micro-
bial cell factories.
Since 2002, Microbial Cell Factories has published more
than 180 relevant manuscripts in form of Research Arti-
cles, Technical Notes, Reviews and Commentaries high-
lighting the role of hosting microbial cells for proteins
and metabolites productions. About one fourth of all the
manuscripts have the yeast Saccharomyces cerevisiae and
other non-conventional yeasts as a subject. Many of these
manuscripts are highly cited and, despite its young age,
the Journal has become already a reference in the current
yeast biotechnology literature.
A simple analysis of the manuscripts published during the
last three decades clearly indicates a transition in the
choice of the different yeast hosts. Indeed, starting from
the early '80s, the majority of recombinant proteins pro-
duced in yeasts have been expressed using the conven-
tional yeast S. cerevisiae. This was a direct reflection of the
familiarity of molecular biologists with this yeast, com-
bined with the deep knowledge about its genetics, bio-
chemistry, physiology and fermentation technologies.
Furthermore, S. cerevisiae is recognized by the American
Food and Drug Administration (FDA) as an organism
"generally regarded as safe" (GRAS). In this respect, it
should be underlined that most of the recombinant phar-
maceuticals so far approved for human use by the FDA
and/or by the European Medicines Agency (EMEA)
obtained by microbial eukaryotic cells have been
obtained almost exclusively using S. cerevisiae [2]. How-
ever, it has to be said that sometimes this yeast is not the
optimal host for large-scale production of heterologous
proteins, especially because of its fermentation needs that
require sophisticated equipment. In addition, the proteins
produced by S. cerevisiae are often hyper-glycosylated and
retention of the products within the periplasmic space,
with a consequent partial degradation, is frequently
observed. Disadvantages such as these have promoted,
since the late '80s, a search for alternative hosts, trying to
exploit the great biodiversity existing among the yeasts,
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and starting the development of expression systems using
the so-called "non-conventional" yeasts.
Based on the manuscripts published by Microb Cell Fact,
the most established alternative host used for the produc-
tion of heterologous proteins is today the yeast Pichia pas-
toris, while S. cerevisiae is still the predominant host used
for metabolite productions. Vaccines [3], receptors [4],
industrial enzymes [5,6] and bacterial toxins [7], are
among the most prominent compounds obtained by
recombinant P. pastoris cell factories. The use of different
promoters, culture medium and operational strategies for
P. pastoris have been reviewed [8]. The analysis of tran-
scriptional levels of the genes involved in protein synthe-
sis and secretion is a key factor to understand the host
organism's responses to recombinant protein production,
as well as their interaction with the growth conditions.
The transcriptional levels of some genes related to the
unfolded protein response (UPR) and central metabolism
have been analysed, revealing that overexpression and
secretion of a recombinant lipase seems to trigger the UPR
in P. pastoris, resulting in a physiological bottleneck for
the production process [5]. However, when the genome
sequence was not available, strain and process develop-
ment relied mainly on analogies to other well studied
yeasts like S. cerevisiae [9]. Finally, the genome of P. pas-
toris has been published [10,11]. A gene annotation http:/
/bioinformatics.psb.ugent.be/webtools/bogas/ and an
open access web based genome browser http://
www.pichiagenome.org are now available to the scientific
community. A tremendous development of this host is
also confirmed by many articles over viewing the develop-
ment of new fermentation [3,4,12,13], scale-up [14] and
modelling [15] strategies. The first example of a metabo-
lite production in P. pastoris is related to the overexpres-
sion of the riboflavin biosynthetic pathway [16].
During the past years, great efforts have been dedicated to
the development of yeasts fermenting xylose efficiently.
Also in this respect, the Pichia genus has been an impor-
tant source of hydrolytic enzymes, especially the ones
involved in the xylose fermentation. The NAD(P)H-
dependent Pichia stipitis xylose reductase (PsXR) is one of
the key enzymes for xylose fermentation, and has been
cloned into the commonly used ethanol-producing yeast
S. cerevisiae. In order to eliminate the redox imbalance due
to the preference of this enzyme for NADPH, successful
strategies have been implemented to alter the coenzyme
specificity [17]. Other non-conventional yeasts
(Hansenula polymorpha, Arxula adeninivorans [18-22], Can-
dida boidinii [22], Pichia methanolica [22], Xanthophyllomy-
ces dendrorhous [23] and Kluyveromyces lactis [24,25]
covered a less relevant space on Microb Cell Fact.
Going back to the prominent role covered by S. cerevisiae,
a clear transition in the application fields has been
observed. Indeed, the majority of the articles published in
these last years by Microb Cell Fact are about the produc-
tion of metabolites instead of heterologous proteins. The
backer's yeast has long been utilized as a very efficient bio-
catalyst, thanks to its enzymatic capabilities, native or
manipulated. Remarkably, it can be easily engineered to
become able to produce small, huge and complex mole-
cules, like a variety of flavonoids [26,27], isoprenoids and
polyunsatured fatty acids [27], biofuels [28], fine chemi-
cals and API (active pharmaceutical ingredient) [29], alka-
loids [30] and organic acids [31]. In very recent years,
many efforts have been devoted to widen the substrate
range for S. cerevisiae. In particular, specific attention has
been dedicate to make S. cerevisiae able to ferment xylose
and/or arabinose [32-36] or to improve its growth on
sucrose [37]. S. cerevisiae has been also the center of atten-
tion as a model for basic and applied virus research,
including the analysis of the function of individual pro-
teins from pathogenic viruses, the elucidation of key proc-
esses in viral replication and the use of this yeast in
antiviral drug development and vaccine production [38].
In this respect, S. cerevisiae metabolome served as a tool to
prioritize host targets [39]. Metabolite profiling has been
also used for the characterization of the metabolic shift
between oxidative and fermentative growth [40] as well as
for the development of new technologies leading to yeast
artificial chromosomes employed for random assembly of
biosynthetic pathways [26]. A couple of articles have also
been published about the modulation of the ribosomal
subunit ratio [41] and regulation of gene expression [42]
to maximize recombinant protein yield in S. cerevisiae, an
enduring bottleneck in the post-genomic sciences.
Finally, an interesting comparative review of different
microbial cell factories for recombinant protein produc-
tion has considerably helped to describe the extremely
rich landscape of in-vivo protein folding processes [43].
The effects of the composition of growth media in relation
to strain development for industrial application and for
heterologous protein and for bulk bio-commodity pro-
duction have also been reviewed [44].
In the end, taking into consideration everything said so
far, Microb Cell Fact articles show that manipulation of
yeast cell factories for improving host properties and pro-
ductions can be obtained by changing the external and/or
the internal environment of the cell. Modulations of cell
performances changing the external environment have
long been and are still practiced by choosing selective
operating conditions during the processes. Traditionally,
internal changes have been and are still achieved by ran-Microbial Cell Factories 2009, 8:51 http://www.microbialcellfactories.com/content/8/1/51
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dom mutagenesis, selection and, more directly, by means
of rDNA approaches.
Based on my experience, I (DP) do believe that the best
yeast cell factory could be obtained by fishing for the wild
type or recombinant yeast cell factory having the best fit-
ness for that specific production/process. I do also believe
that it will be obtained by a deep analysis and following
direct engineering of the whole set of biochemical reac-
tions involved in the biosynthesis. Judging from the arti-
cles published by Microb Cell Fact, it seems clear that the
first approach is more successful for the production of
metabolites, while the second is for the production of pro-
teins. At the same, we are both aware that selection
remains the most powerful tool to catch the desired cell
factory.
Concluding, the ideal solution would be a laboratory cre-
ated biological system capable of replication and evolu-
tion, fed only by simple carbon and energy sources. The
future is already under way: the chemical synthesis,
assembly, and cloning of a bacterial genome in S. cerevi-
siae has been already described [45,46].
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